Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Selvigaltin by Galecto for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Selvigaltin is under clinical development by Galecto and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....
Selvigaltin by Galecto for Metastatic Melanoma: Likelihood of Approval
Selvigaltin is under clinical development by Galecto and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Galecto's Selvigaltin?
Selvigaltin is a small molecule commercialized by Galecto, with a leading Phase II program in Decompensated Cirrhosis. According to Globaldata,...